2CJP, also known as 4-(4-bromo-2,5-dimethoxyphenyl)-2,3,4,5-tetrahydro-1H-2-benzazepine, is a serotonin receptor modulator of the phenethylamine, 2C, and N-benzylphenethylamine families. It is a cyclized phenethylamine analogue of 25B-NBOMe in which the N-benzylethylamine side chain has been cyclized to form a tetrahydrobenzazepine ring. The drug shows affinity for the serotonin 5-HT2A and 5-HT2C receptors (Ki = 19–457nM and 227–3,240nM, respectively). 2CJP was first described in the scientific literature by Michael Robert Braden of the lab of David E. Nichols at Purdue University in 2007.

See also

External links